Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502813 · ClinicalTrials.gov registry record · NA
Citicoline, Creatine, and Omega-3 Effects in Middle Age Women
A NA study of Cognitive Benefits, sponsored by Deborah Yurgelun-Todd.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01502813: Completed NA study of Cognitive Benefits, sponsored by Deborah Yurgelun-Todd.
NCT01502813 is a NA study of Cognitive Benefits that has completed, run by Deborah Yurgelun-Todd. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01502813, a NA study of Cognitive Benefits, has completed, sponsored by Deborah Yurgelun-Todd.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the functional effects of a citicoline, creatine, and omega-3 fatty acids combination when administered for a duration of four weeks (28 days) to non-psychiatric adult female participants.
Primary Outcome
List B in the California Verbal Learning Test (CVLT) score range 1-16; the score is the number of words recalled so higher scores = better performance/more words recalled.
Conditions Studied
Interventions
- DRUG Citicoline, Omega-3 Fatty Acids and Creatine
Study Locations (1)
Utah
- The Brain Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-02-01 |
| Est. Completion | 2019-11-01 |
| Phase | NA |
What the finished NCT01502813 record still lists
NCT01502813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Cognitive Benefits appearing as the primary indexed condition, and to 1 intervention - of which Citicoline, Omega-3 Fatty Acids and Creatine is the first listed.
NCT01502813 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT01502813 about?
NCT01502813 is a clinical study titled "Citicoline, Creatine, and Omega-3 Effects in Middle Age Women". The purpose of this study is to determine the functional effects of a citicoline, creatine, and omega-3 fatty acids combination when administered for a duration of four weeks (28 days) to non-psychiatric adult female participants.
What is the current status of trial NCT01502813?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2012-02-01. Estimated completion is 2019-11-01.
What conditions does trial NCT01502813 study?
This clinical trial studies the following conditions: Cognitive Benefits.
What interventions are being tested in trial NCT01502813?
The interventions under investigation include: Citicoline, Omega-3 Fatty Acids and Creatine (DRUG).
Who is sponsoring clinical trial NCT01502813?
This trial is sponsored by Deborah Yurgelun-Todd, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01502813 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01502813's enrollment target sits among peer trials
40 1447th of 2000 higher than 465 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI